Skip to main content
Caplight Logo









Kurome Therapeutics

Kurome Therapeutics

Private
Cincinnati, OhioHealthcare & Life Scienceshttp://kurometherapeutics.com/

Last Round

Series A

Jun 10, 2021

Total Funding Raised

$19M

Company Overview

Kurome Therapeutics is a biotechnology company that develops small-molecule therapies targeting dysregulated immune signaling pathways in hematological cancers such as acute myeloid leukemia and myelodysplastic syndromes.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologysmall-molecule inhibitordrug discoveryacute myeloid leukemiaAMLmyelodysplastic syndromesMDSkinase inhibitoroncologyclinical trialsprecision medicinecancer therapeuticsdrug developmentbiotech startuppharma pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kurome Therapeutics Comparables

Compare Kurome Therapeutics with similar companies based on industry and business-model similarity.

Kurome Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Eilean Therapeutics
93%
Arog Pharmaceuticals
86%
Hangzhou Polymed Biopharmaceuticals
83%

Kurome Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 10, 2021
SeedApr 29, 2020

Key People

Founding team and executive leadership

Jan Rosenbaum

President, Chief Executive Officer, CSO

Executive Team

Kurome Therapeutics Investors

Notable investors and investment history

Kurome Therapeutics investors
InvestorRounds
QCA VenturesSeed, Series A
CincyTechSeries A, Seed
Angel Physicians FundSeed
MedicxiSeries A
Affinity Asset AdvisorsSeries A

Kurome Therapeutics Filings

Explore SEC and related filing metadata, where available.

Kurome Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Kurome Therapeutics's valuation, stock price, and market status.

Is Kurome Therapeutics a public or private company?

Kurome Therapeutics is a private company.

What is the current stock price of Kurome Therapeutics?

Kurome Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Kurome Therapeutics worth (valuation)?

Valuation information for Kurome Therapeutics is not publicly available.

Can I buy Kurome Therapeutics stock?

Kurome Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Kurome Therapeutics's last funding round?

Kurome Therapeutics's most recent funding round was Series A on June 10, 2021.

Who are the main investors in Kurome Therapeutics?

Key investors in Kurome Therapeutics include CincyTech, Medicxi, Affinity Asset Advisors.

Will Kurome Therapeutics IPO soon?

No public IPO plans have been announced for Kurome Therapeutics.

How can I track Kurome Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Kurome Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCincinnati, Ohio
Employee Range1
Year Founded2019
Last FundingJun 10, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?